Oximio announces new Chief Operating Officer - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Oximio announces new Chief Operating Officer

19 Apr 2021

Sponsored by Oximio Sponsored by Visit Company
Oximio announces new Chief Operating Officer

Clinical trial services provider, Oximio, announced in March that Peter Szabados has been appointed as the Chief Operating Officer (COO), joining the leadership team to enhance the client-focused operation.

“We are excited to bring Peter on board to benefit from his impressive experience and operational expertise,” said Krisztina Varga, Chief Executive Officer. “Peter’s role will be to lead and foster a client-focused and solution-oriented operation, and to help Oximio evolve to the next stage on the journey of becoming the first-choice for the provision of clinical trials services.”

“Throughout my career I have always worked to create something new. Oximio has had a very impressive track record of development since it was founded, and I believe it has a huge potential. I am happy and excited to become part of the team that will take Oximio to the next level.” – said Peter Szabados.

Szabados brings a wealth of international leadership experience. In the past 20+ years, Peter worked for market leading, global logistics service providers in several operations management positions before becoming a Managing Director. Lately, he has had global responsibilities in logistics innovation, non-conventional supply chain product development and turnaround projects. His cross-vertical experience has a track record in implementations, business turnaround, change management and process optimization through collaborative relationships. Peter is of a cosmopolitan mindset, his resumé includes working in multiple countries and holding regional and global roles.

Free Whitepaper

Regional Focus: In the Front Lines of Clinical Trials

Oximio is a well-established clinical trials service provider that helps researchers around the world discover effective treatments and cures for medical needs. With a global presence spanning regions such as the UK, Eastern Europe, Western Asia, and South Africa, Oximio harnesses a deep understanding of a range of international clinical trial markets. Focusing on its Eastern European operations, this whitepaper provides an overview of the Russian, Georgian and Ukranian clinical trial landscape, including discussions of the unique advantages and opportunities that each market presents.

The whitepaper explores the local regulations and legislation that govern clinical research in these markets, as well as the steps and processes that researchers must take to secure approval and register drugs there. The key services provided by Oximio to support clinical trials in these countries are also detailed, including fact sheets on the service provider’s local depots, capacities and operational timelines.

By clicking the “Submit” button above, you accept and acknowledge that your data will be used as described in the Oximio Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.